Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab - Wikidata - wikimedia - TriplyDB

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

http://www.wikidata.org/entity/Q28080677

about

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

http://www.wikidata.org/entity/Q28080677

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

@ast

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

@en

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

@nl

type

label

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

@ast

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

@en

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

@nl

prefLabel

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

@ast

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

@en

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

@nl

P1433

Q28080677-370EAEE9-D201-4D33-A6C3-BBA5317F8DF9

P1476

Q28080677-95FF056E-F405-407C-B272-B00268D0C7A2

P2093

Q28080677-4CC97CAD-428D-47D9-BBD5-9FCD0A09C1CF

Q28080677-4EC609D5-8FB8-43D7-B34A-33E6B3F7258A

P2860

Q28080677-0A672E92-9688-4E26-B3A5-41B3A9B4AC43

Q28080677-0B06F638-6951-4C4E-84A2-755CCF976125

Q28080677-0C72E828-53B3-4A31-9F3C-BD3AA822CB70

Q28080677-2257C46B-94E8-4DD8-905D-D3024FFD6C2E

Q28080677-247D3550-25F8-4140-86FD-3FBCC93920FA

Q28080677-3169EA75-B67D-4A54-98D9-F6070739FD36

Q28080677-33010166-9630-4DCF-B6E2-D01FE4466375

Q28080677-350B3BC2-535D-4506-942A-82E89C333735

Q28080677-42ED164D-9EC9-40EC-994A-7AC4177BA888

Q28080677-43BB1964-9243-4451-AF7F-9B1B0A30F680

P2888

Q28080677-F487A9C1-CB73-4370-8DC4-0EA73803BFC6

P304

Q28080677-FB691CAC-81F7-4DA1-8D17-1B0E4020C100

P31

Q28080677-26681815-13A9-4759-80D5-1E51657C2F12

P356

Q28080677-0061C09A-AA84-4107-BA65-55563C591020

P407

Q28080677-41C48C29-A548-44BB-BC14-3E4017B8E73C

P433

Q28080677-B9DE283B-F871-4816-9011-FD871D4C1D31

P478

Q28080677-81B5FAE3-2A31-4249-BD12-10C59C11C195

P577

Q28080677-CF2B7040-F33A-49EE-B4A4-1DF3CDD1E4C7

P6179

Q28080677-00FB7C1A-71C8-48E7-A537-6D91DEF735D9

P698

Q28080677-9835B2DE-22E7-4ED9-A214-8792F6676C11

P932

Q28080677-7FC1BEED-1736-4E4D-A582-71F6C5D9453B

P356

S40744-014-0007-2

P1433

Rheumatology and therapy

P1476

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

@en

P2093

Andra F. Negoescu

http://www.w3.org/2001/XMLSchema#string

Andrew J. K. Östör

http://www.w3.org/2001/XMLSchema#string

P2860

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analy

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Acute-phase proteins and other systemic responses to inflammation

Evolving concepts of rheumatoid arthritis

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

Anakinra treatment of patients with rheumatoid arthritis.

P2888

s40744-014-0007-2

P304

17-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40744-014-0007-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014614447

http://www.w3.org/2001/XMLSchema#string

P698

27747493

http://www.w3.org/2001/XMLSchema#string

P932

4883250

http://www.w3.org/2001/XMLSchema#string